According to Josh Halpern, Co-Founder and CEO of IntegriChain, They are thrilled to have an industry icon of Jim’s caliber lead our board as our company matures. He has extraordinarily in-depth knowledge of every area of medication availability and commercialization, including the introduction of ground-breaking treatments for hepatitis C and HIV that affected millions of people. Jim’s experience and insights will strengthen our capacity to support pharmaceutical makers in overcoming these obstacles and bringing innovative science to market as the industry deals with the harsh reality of net revenue reduction and difficult patient access.
Jim’s remarkable accomplishments lie precisely at the nexus of pharmaceutical commercialization, public policy, and price. IntegriChain will be able to expand and grow thanks to his special abilities and understanding. Daniel Berglund, co-head of healthcare at Nordic Capital Investment Advisors and a board member of IntegriChain, expressed the board’s excitement about bringing in more knowledge to strengthen the company’s leadership and encourage the growth of its product offerings.
Meyers said he was honored to be included to the IntegriChain board at this critical juncture. The business has grown into a preeminent platform for net revenue optimization, tackling a critical obstacle that faces medicine commercialization in the contemporary market. He is excited to carry out our plan for IntegriChain, which is to use our special blend of enterprise-class technology, scalable outsourcing, strategy creation, and analytics to lead the sector in net revenue performance.
With over thirty years of expertise in pharmaceutical operations and commercialization, Jim Meyers provides a wide breadth of knowledge. Having led two of the most successful launches in pharmaceutical history for hepatitis C, he has experience in commercial and corporate strategy, pricing, market access, and payer strategy. He also has a deep understanding of the intersection of public policy, pricing, and access, as well as the ongoing drug pricing debate in Washington, DC. Meyers is among a select group of executives who spearheaded Gilead Sciences’ transformation from a start-up to one of the world’s most prosperous biopharmaceutical firms. Before leaving in 2018, he was the Chief Commercial Officer and Executive Vice President of Worldwide Commercial Operations at Gilead. Over the course of his 22-year employment, he oversaw the commercial strategy, branding, positioning, pricing, and forecasting for the introduction of over 20 goods, including 11 brands with peak yearly revenue of more than $1 billion. Meyers has been a Senior Advisor at Gilead and the Boston Consulting Group, among other biopharmaceutical businesses, since 2018. Sangamo Therapeutics, CytomX Therapeutics, and Arbutus Biopharma are the three publicly traded biotech businesses he serves on the board of. He graduated from Boston College with a BS in Economics.
IntegriChain assists pharmaceutical companies in commercializing their research, guaranteeing that patients will have timely, cost-effective, and long-lasting access to treatment. Pharma may now use the sole data-driven commercialization platform, from strategy to operational execution, thanks to IntegriChain. The Company connects the commercial, financial, and operational aspects of drug access and profitability through its distinct focus on data, technology, consulting, and outsourcing. Pharma innovators can get enhanced commercial results by digitizing routine and everyday business tasks and merging data and operations from contracting, pricing, channel and distribution, and gross-to-net with IntegriChain’s ICyte Platform. Nordic Capital, a well-known sector-specialized private equity investor with a sizable portfolio in healthcare and pharmaceuticals and offices in Ambler, Pennsylvania, and Pune, India, supports IntegriChain.
